Logo image of FENC

FENNEC PHARMACEUTICALS INC (FENC) Stock Price, Quote, News and Overview

NASDAQ:FENC - Nasdaq - CA31447P1009 - Common Stock - Currency: USD

8.32  +0.48 (+6.12%)

After market: 8.32 0 (0%)

FENC Quote, Performance and Key Statistics

FENNEC PHARMACEUTICALS INC

NASDAQ:FENC (8/4/2025, 8:01:02 PM)

After market: 8.32 0 (0%)

8.32

+0.48 (+6.12%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High9.3
52 Week Low3.96
Market Cap229.80M
Shares27.62M
Float22.83M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE9.88
Earnings (Next)08-07 2025-08-07/bmo
IPO06-05 2001-06-05


FENC short term performance overview.The bars show the price performance of FENC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

FENC long term performance overview.The bars show the price performance of FENC in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40

The current stock price of FENC is 8.32 USD. In the past month the price decreased by -1.77%. In the past year, price increased by 40.3%.

FENNEC PHARMACEUTICALS INC / FENC Daily stock chart

FENC Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.62 348.32B
AMGN AMGEN INC 14.54 162.36B
GILD GILEAD SCIENCES INC 14.79 142.44B
VRTX VERTEX PHARMACEUTICALS INC N/A 121.28B
REGN REGENERON PHARMACEUTICALS 12.52 61.71B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 54.71B
ARGX ARGENX SE - ADR 74.47 42.25B
ONC BEONE MEDICINES LTD-ADR 7.82 32.93B
BNTX BIONTECH SE-ADR N/A 26.45B
SMMT SUMMIT THERAPEUTICS INC N/A 21.78B
INSM INSMED INC N/A 21.10B
BIIB BIOGEN INC 8.26 19.37B

About FENC

Company Profile

FENC logo image Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Company Info

FENNEC PHARMACEUTICALS INC

PO Box 13628, 68 Tw Alexander Dr

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US

CEO: Rostislav Raykov

Employees: 32

FENC Company Website

FENC Investor Relations

Phone: 19196364530

FENNEC PHARMACEUTICALS INC / FENC FAQ

What is the stock price of FENNEC PHARMACEUTICALS INC today?

The current stock price of FENC is 8.32 USD. The price increased by 6.12% in the last trading session.


What is the ticker symbol for FENNEC PHARMACEUTICALS INC stock?

The exchange symbol of FENNEC PHARMACEUTICALS INC is FENC and it is listed on the Nasdaq exchange.


On which exchange is FENC stock listed?

FENC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for FENNEC PHARMACEUTICALS INC stock?

11 analysts have analysed FENC and the average price target is 13.06 USD. This implies a price increase of 56.92% is expected in the next year compared to the current price of 8.32. Check the FENNEC PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is FENNEC PHARMACEUTICALS INC worth?

FENNEC PHARMACEUTICALS INC (FENC) has a market capitalization of 229.80M USD. This makes FENC a Micro Cap stock.


How many employees does FENNEC PHARMACEUTICALS INC have?

FENNEC PHARMACEUTICALS INC (FENC) currently has 32 employees.


What are the support and resistance levels for FENNEC PHARMACEUTICALS INC (FENC) stock?

FENNEC PHARMACEUTICALS INC (FENC) has a support level at 7.83 and a resistance level at 8.6. Check the full technical report for a detailed analysis of FENC support and resistance levels.


Is FENNEC PHARMACEUTICALS INC (FENC) expected to grow?

The Revenue of FENNEC PHARMACEUTICALS INC (FENC) is expected to decline by -16.58% in the next year. Check the estimates tab for more information on the FENC EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy FENNEC PHARMACEUTICALS INC (FENC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does FENNEC PHARMACEUTICALS INC (FENC) stock pay dividends?

FENC does not pay a dividend.


When does FENNEC PHARMACEUTICALS INC (FENC) report earnings?

FENNEC PHARMACEUTICALS INC (FENC) will report earnings on 2025-08-07, before the market open.


What is the Price/Earnings (PE) ratio of FENNEC PHARMACEUTICALS INC (FENC)?

FENNEC PHARMACEUTICALS INC (FENC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).


What is the Short Interest ratio of FENNEC PHARMACEUTICALS INC (FENC) stock?

The outstanding short interest for FENNEC PHARMACEUTICALS INC (FENC) is 5.71% of its float. Check the ownership tab for more information on the FENC short interest.


FENC Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to FENC. When comparing the yearly performance of all stocks, FENC is one of the better performing stocks in the market, outperforming 89.98% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

FENC Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to FENC. FENC may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

FENC Financial Highlights

Over the last trailing twelve months FENC reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS decreased by -666.67% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -31.11%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-108.51%
Sales Q2Q%-65.52%
EPS 1Y (TTM)-666.67%
Revenue 1Y (TTM)-31.25%

FENC Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 85% to FENC. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 308694732858483400% and a revenue growth -16.58% for FENC


Ownership
Inst Owners56.62%
Ins Owners1.91%
Short Float %5.71%
Short Ratio14.94
Analysts
Analysts85.45
Price Target13.06 (56.97%)
EPS Next Y308694732858483400%
Revenue Next Year-16.58%